Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV vaccination impact and implementer training feasibility study using first-void urine sampling
PACTR202502637719320Not yet recruiting
- Sponsor
- University of Antwerp
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Open-label trial of Walrinvax in human papillomavirus infection (4 cohorts), sponsored by University of Antwerp. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202502637719320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502637719320.